Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coumarins | 4 | 2015 | 45 | 0.660 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2014 | 31 | 0.380 |
Why?
|
| Estrogens | 2 | 2013 | 203 | 0.370 |
Why?
|
| Stilbenes | 2 | 2009 | 44 | 0.320 |
Why?
|
| Drug Design | 3 | 2007 | 186 | 0.280 |
Why?
|
| Breast Neoplasms | 4 | 2013 | 1723 | 0.270 |
Why?
|
| Thiophenes | 1 | 2007 | 32 | 0.250 |
Why?
|
| Ribonucleosides | 2 | 2000 | 3 | 0.190 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2676 | 0.170 |
Why?
|
| Antiviral Agents | 2 | 2000 | 195 | 0.160 |
Why?
|
| Cell Cycle | 3 | 2015 | 346 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2013 | 301 | 0.130 |
Why?
|
| Antineoplastic Agents | 4 | 2011 | 1019 | 0.120 |
Why?
|
| Matrix Metalloproteinases | 1 | 2015 | 49 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1124 | 0.110 |
Why?
|
| Prodrugs | 3 | 2003 | 31 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 127 | 0.110 |
Why?
|
| Zidovudine | 2 | 2003 | 32 | 0.100 |
Why?
|
| Proteome | 1 | 2014 | 152 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 140 | 0.090 |
Why?
|
| Estradiol | 1 | 2014 | 268 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 532 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 495 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 378 | 0.090 |
Why?
|
| Structure-Activity Relationship | 3 | 2010 | 506 | 0.090 |
Why?
|
| Tamoxifen | 2 | 2010 | 69 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2010 | 47 | 0.080 |
Why?
|
| Humans | 11 | 2015 | 43102 | 0.080 |
Why?
|
| Artemia | 1 | 2009 | 13 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2010 | 183 | 0.080 |
Why?
|
| Pyrrolidines | 1 | 2009 | 31 | 0.080 |
Why?
|
| Piperidines | 1 | 2009 | 83 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1455 | 0.070 |
Why?
|
| Anti-HIV Agents | 3 | 2003 | 486 | 0.070 |
Why?
|
| Toremifene | 1 | 2007 | 4 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 291 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 121 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1092 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2003 | 465 | 0.050 |
Why?
|
| Prednisolone | 1 | 2004 | 16 | 0.050 |
Why?
|
| Stereoisomerism | 2 | 2004 | 169 | 0.050 |
Why?
|
| Valine | 1 | 2003 | 29 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2003 | 57 | 0.050 |
Why?
|
| Nucleosides | 2 | 2002 | 30 | 0.050 |
Why?
|
| Rats | 5 | 2011 | 3735 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 187 | 0.040 |
Why?
|
| Apoptosis | 1 | 2009 | 1568 | 0.040 |
Why?
|
| Female | 3 | 2013 | 24698 | 0.040 |
Why?
|
| Liver | 3 | 2011 | 511 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2011 | 157 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2000 | 18 | 0.040 |
Why?
|
| Acetylation | 1 | 2000 | 107 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2000 | 247 | 0.040 |
Why?
|
| Tubercidin | 1 | 1997 | 4 | 0.030 |
Why?
|
| Animals | 6 | 2011 | 16992 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2010 | 876 | 0.030 |
Why?
|
| HIV-1 | 1 | 2000 | 755 | 0.030 |
Why?
|
| Cell Line | 2 | 2011 | 1410 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 945 | 0.020 |
Why?
|
| Biological Assay | 1 | 2009 | 63 | 0.020 |
Why?
|
| Larva | 1 | 2009 | 133 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 224 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 411 | 0.020 |
Why?
|
| Molecular Structure | 2 | 1998 | 570 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 458 | 0.010 |
Why?
|
| Esterases | 1 | 2004 | 8 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 37 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 63 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2004 | 97 | 0.010 |
Why?
|
| Esterification | 1 | 2003 | 6 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 4 | 0.010 |
Why?
|
| Reference Standards | 1 | 2003 | 55 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 63 | 0.010 |
Why?
|
| Biotransformation | 1 | 2003 | 69 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2003 | 104 | 0.010 |
Why?
|
| Drug Stability | 1 | 2004 | 129 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 116 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 260 | 0.010 |
Why?
|
| Flucytosine | 1 | 2002 | 1 | 0.010 |
Why?
|
| Nucleoside Deaminases | 1 | 2002 | 7 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2002 | 4 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2002 | 9 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 2002 | 7 | 0.010 |
Why?
|
| Immunoconjugates | 1 | 2002 | 8 | 0.010 |
Why?
|
| Nucleotides | 1 | 2002 | 37 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 611 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 1766 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1997 | 41 | 0.010 |
Why?
|
| Male | 1 | 2014 | 23409 | 0.010 |
Why?
|